BASiBroadcast

As a company that’s been around for over 42 years, we’ve held a front-row seat to the unrelenting demands for innovation, and continuously strive to meet and surpass those demands as the contract research industry evolves. Keeping pace with new technologies and instrumentation is essential to our work and to the success of our clients, partners and ultimately, patients waiting for treatment.

Since reengaging with BASi in 2017, I've seen positive trends that matter for 2018. We've had four consecutive quarters with positive earnings after a rough decade with both a slowly recovering economy and ongoing restructuring of the biopharma industry. Investing in growth is a priority. It is well recognized that life science innovation is very healthy, with new initiatives taking hold in editing out genetic abnormalities and marshaling the immune system to help root out a variety of cancers. The FDA approved many new therapies in 2017 and now promises to ease the way to more.